Carlo Castellani
Nephrology — Istituto Giannina Gaslini, Italy
Carlo Castellani
LeadR Profile
Nephrology
Subspecialties: Pulmonology - Public Health - Neonatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1993 - 2026
Number : 224
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study. safety, fibrosis, cystic fibrosis, adolescent, genotype, therapeutics | Ann Am Thorac Soc | 2026 | 0 |
| [Italian Cystic Fibrosis Registry (ICFR). Report 2023-2024]. registries, genes, pregnancy, parenting, mortality, epidemiology, lung, incidence, fibrosis, preventive medicine, aged, cystic fibrosis, prevalence, alleles, diagnosis, transplants, therapeutics, software, infections | Epidemiol Prev | 2026 | 0 |
| Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. cells, cystic fibrosis, alleles, therapeutics | J Cyst Fibros | 2026 | 0 |
| Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population. sars-cov-2, lung, hospitalization, fibrosis, cystic fibrosis, covid-19, transplants, severe acute respiratory syndrome-related coronavirus, organ transplantation, transplantation, infections | J Cyst Fibros | 2026 | 0 |
| Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World Study. cells, fibrosis, critical care, cystic fibrosis, therapeutics | Am J Respir Crit Care Med | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study of VX 121 Combination Therapy in Subjects With Cystic Fibrosis 2024-514173-22-00 — safety, fibrosis, cystic fibrosis, therapeutics | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map